Loading...
Loading...
Browse all stories on DeepNewz
VisitJ&J: Dexamethasone Reduces Infusion Reactions in Lung Cancer Patients by 22.5%
Sep 10, 2024, 09:19 PM
Johnson & Johnson ($JNJ) has announced that dexamethasone reduces infusion-related reactions in patients with EGFR-mutated non-small cell lung cancer treated with intravenous Rybrevant (amivantamab-vmjw). The prophylaxis regimen with 8 mg dexamethasone taken for two days prior to the first infusion met the primary endpoint of incidence of infusion-related reactions at C1D1. Ongoing studies are evaluating additional prophylactic strategies to further reduce these reactions. The pre-medication regimen showed an infusion-related reaction rate of 22.5% with intravenous Rybrevant.
View original story
Markets
Yes • 50%
No • 50%
FDA approval announcements
No • 50%
Yes • 50%
Johnson & Johnson official press release or peer-reviewed publication
No • 50%
Yes • 50%
Stock market data from a reliable financial source (e.g., Bloomberg, Yahoo Finance)
Significant reduction in reactions • 25%
Increase in reactions • 25%
No significant change • 25%
Moderate reduction in reactions • 25%
Johnson & Johnson official press release or peer-reviewed publication
20% to 25% • 25%
More than 30% • 25%
Less than 20% • 25%
25% to 30% • 25%
Johnson & Johnson official press release or peer-reviewed publication
None of the above • 25%
Dexamethasone • 25%
Alternative corticosteroid • 25%
Combination therapy • 25%
Johnson & Johnson official press release or peer-reviewed publication